Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 36.1
edited by manuelmenendez
on 2025/02/02 00:50
on 2025/02/02 00:50
Change comment:
There is no comment for this version
To version 5.1
edited by manuelmenendez
on 2025/01/27 23:04
on 2025/01/27 23:04
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
-
Attachments (0 modified, 0 added, 1 removed)
-
Objects (1 modified, 0 added, 2 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,10 +2,9 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensionaldiagnostic framework for CNS diseases//=5 += Neurodiagnoses = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 -We aim to create a structured, interpretable, and scalable diagnostic tool. 7 +This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool. 9 9 ))) 10 10 ))) 11 11 ... ... @@ -13,104 +13,26 @@ 13 13 ((( 14 14 (% class="col-xs-12 col-sm-8" %) 15 15 ((( 16 -= What is this about and whatcan I find here? =15 += What can I find here? = 17 17 18 -= **Overview**=17 +== Who has access? == 19 19 19 +We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 20 20 21 - Theclassificationand diagnosis of central nervoussystem (CNS) diseases have long been constrainedby traditional phenotype-based approaches, which often fail to capturethecomplex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes that drive disease progression. Neurodegenerative and psychiatric disorders, for example, exhibit significant clinical overlap, co-pathology, and heterogeneity, making current diagnostic models insufficient.21 +== How to Contribute: == 22 22 23 -This project proposes a new diagnostic framework—one that shifts from symptom-based classifications to an etiology-driven, tridimensional system. By integrating genetics, proteomics, neuroimaging, computational modeling, and AI-powered annotations, this approach aims to provide a more precise, scalable, and biologically grounded method for diagnosing and managing CNS diseases. 24 - 25 -The AI-powered annotation system plays a critical role by structuring, interpreting, and tracking multi-modal data, ensuring real-time disease progression analysis, clinician decision support, and personalized treatment pathways. 26 - 27 -=== **Project Aim** === 28 - 29 -The project aims to develop a tridimensional diagnostic framework with an AI-powered annotation system, integrating etiology, molecular biomarkers, and neuroanatomoclinical correlations for precise, standardized, and scalable CNS disease diagnostics. 30 - 31 -The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 32 - 33 -* **Axis 1**: Etiology (genetic or other causes of diseases). 34 -* **Axis 2**: Molecular Markers (biomarkers). 35 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 36 - 37 -This methodology enables: 38 - 39 -* Greater precision in diagnosis. 40 -* Integration of incomplete datasets using AI-driven probabilistic modeling. 41 -* Stratification of patients for personalized treatment. 42 - 43 -== **The Role of AI-Powered Annotation** == 44 - 45 -To enhance standardization, interpretability, and clinical application, the framework integrates an AI-powered annotation system, which: 46 - 47 -* Assigns structured metadata tags to diagnostic features. 48 -* Provides real-time contextual explanations for AI-based classifications. 49 -* Tracks longitudinal disease progression using timestamped AI annotations. 50 -* Improves AI model transparency through interpretability tools (e.g., SHAP analysis). 51 -* Facilitates decision-making for clinicians by linking annotations to standardized biomedical ontologies (SNOMED, HPO). 52 - 53 -== **The case of neurodegenerative diseases** == 54 - 55 -There have been described these 3 diagnostic axes: 56 - 57 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 58 - 59 -* ((( 60 -**Axis 1: Etiology** 61 - 62 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 63 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 64 -* //Tests//: Genetic testing, lifestyle, and cardiovascular screening. 65 - 66 - 67 -))) 68 -* ((( 69 -**Axis 2: Molecular Markers** 70 - 71 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. 72 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. 73 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). 74 - 75 - 76 -))) 77 -* ((( 78 -**Axis 3: Neuroanatomoclinical** 79 - 80 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. 81 -* //Examples//: Hippocampal atrophy correlating with memory deficits. 82 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. 83 -))) 84 - 85 -== **Applications** == 86 - 87 -This system enhances: 88 - 89 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials. 90 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. 91 - 92 -== How to Contribute == 93 - 94 94 * Access the `/docs` folder for guidelines. 95 95 * Use `/code` for the latest AI pipelines. 96 96 * Share feedback and ideas in the wiki discussion pages. 97 97 98 -== Key Objectives == 27 +== Key Objectives: == 99 99 100 100 * Develop interpretable AI models for diagnosis and progression tracking. 101 101 * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. 102 102 * Foster collaboration among neuroscientists, AI researchers, and clinicians. 103 - 104 -== Who has access? == 105 - 106 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 107 107 ))) 108 108 109 109 110 - 111 - 112 - 113 - 114 114 (% class="col-xs-12 col-sm-4" %) 115 115 ((( 116 116 {{box title="**Contents**"}} ... ... @@ -117,15 +117,11 @@ 117 117 {{toc/}} 118 118 {{/box}} 119 119 120 -== Main contents == 41 +== Main contents: == 121 121 122 122 * `/docs`: Documentation and contribution guidelines. 123 123 * `/code`: Machine learning pipelines and scripts. 124 124 * `/data`: Sample datasets for testing. 125 125 * `/outputs`: Generated models, visualizations, and reports. 126 -* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] 127 -* [[Notebooks>>Notebooks]] 128 -* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] 129 -* [[to-do-list>>to-do-list]] 130 130 ))) 131 131 )))
- tridimensional.png
-
- Author
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.manuelmenendez - Size
-
... ... @@ -1,1 +1,0 @@ 1 -149.8 KB - Content
- Collaboratory.Apps.Collab.Code.CollabClass[0]
-
- Public
-
... ... @@ -1,1 +1,1 @@ 1 - Yes1 +No
- XWiki.XWikiRights[3]
-
- Allow/Deny
-
... ... @@ -1,1 +1,0 @@ 1 -Allow - Levels
-
... ... @@ -1,1 +1,0 @@ 1 -view - Users
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.XWikiGuest
- XWiki.XWikiRights[4]
-
- Allow/Deny
-
... ... @@ -1,1 +1,0 @@ 1 -Allow - Groups
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.XWikiAllGroup - Levels
-
... ... @@ -1,1 +1,0 @@ 1 -view